News
Could Aiken pull off a congressional surprise?
Political expert says singer has ‘zero’ chance of winning N.C. district
Clay Aiken‘s potential candidacy for Congress is stirring debate (Washington Blade file photo by Michael Key).
The possibility of a Clay Aiken candidacy for Congress has generated significant buzz as political observers say the gay singer and “American Idol” runner-up has plenty to offer, although big questions remain about whether he could pull off a win.
Last week, the Washington Blade first reported that Clay Aiken was “actively considering” a run for North Carolina’s 2nd congressional district. In a follow-up report, the Washington Post confirmed that Aiken was weighing a bid for the seat, which is currently held by Rep. Renee Ellmers (R-N.C.).
Democratic sources familiar with his plans told the Blade that Aiken has spoken with the Democratic Congressional Campaign Committee, met with political operatives in Washington and Raleigh and paid a visit to the D.C.-based Hart Research Associates to examine polling.
It’s unclear when — if at all — Aiken will make an announcement on whether he’ll pursue a bid for Congress. Via Twitter, Raleigh news affiliate WRAL-TV reported that Aiken told a station producer prior to the Blade report that he wasn’t running for Congress, but the singer hasn’t said anything about a run directly since the Blade broke the story last week.
Ian Palmquist, former chief of Equality North Carolina, said he thinks the general election in a district largely comprised of the Raleigh suburbs, will be tough for any Democrat, but not impossible for Aiken.
“Clay Aiken has some real strengths: He’s from the district, he’s a former teacher, he’s well-liked, and saying he has name recognition is an understatement,” Palmquist said. “To be a strong candidate he would have to show voters a more policy-oriented side than they know him for now and earn the support of key primary constituencies, including African Americans.”
Palmquist added Aiken’s fame alone from his music and Broadway career after his 2003 stint on “American Idol” won’t be enough to propel him to victory.
“His fan base doesn’t necessarily align with his progressive politics, so he would have to expand his base of support significantly to succeed,” Palmquist said.
Although a Republican currently sits in U.S. House seat for North Carolina’s 2nd congressional district, the area was formerly represented by a Democrat in Congress prior to redistricting and the Tea Party boomlet in 2010.
Still, the district is favorable to Republicans. Ellmers won re-election in the district by taking 55.9 percent of the vote in the 2012 election — a year that was favorable to Democrats. Moreover, Republican presidential nominee Mitt Romney in the same year beat Obama in the district by 15.6 points.
Stuart Rothenberg, editor of the Rothenberg Political Report, said Aiken doesn’t have a prayer in the general election against Ellmers.
“His chances of winning the general election? Probably approaching zero,” Rothenberg said. “And that’s being generous. Both McCain and Romney carried the district easily. It isn’t competitive, especially in a midterm election with President Obama’s job approval sitting where it is nationally.”
Aiken, who came out as gay in 2008 in People magazine, also would have competition for the Democratic nomination to run for the seat. Former North Carolina Commerce Secretary Keith Crisco officially announced his candidacy on Monday. Also in the ring is Houston Barnes, an attorney.
The filing deadline to participate in the primary is Feb. 28. The primary itself in North Carolina is set for May 6.
The DCCC hasn’t responded to the Blade’s request for comment on a potential run by Aiken for weeks — before and after the initial report. DCCC spokesperson David Bergstein wouldn’t confirm his interest in running to other media outlets, including Politico, but said Ellmers deserves a challenger.
“Congresswoman Ellmers is responsible for the most unpopular and reckless Congress in history that’s put the middle class at greater risk but it’s up to potential candidates to talk about whether they’re interested in running for Congress, not us,” Bergstein reportedly said.
The Ellmers campaign declined to comment on the possibility of going up against Aiken during the general election.
Although the “American Idol” runner-up is best known for his music and Broadway career, he’s also drawn on his fame to promote causes as an activist. He co-founded the the National Inclusion Project, formerly the Bubel/Aiken Foundation, which seeks to help children with disabilities. Tapped as a national ambassador for the United States Fund for UNICEF in 2004, Aiken has travelled to Afghanistan, Indonesia, Uganda, Mexico, Kenya and Somalia as part of aid missions.
He’s also taken part in LGBT activism. In 2012, just before North Carolina voted to approve a ban on same-sex marriage known as Amendment One, Aiken appeared on CBS’ “Face the Nation” to speak out against the measure.
In 2010, the singer appeared at a briefing on Capitol Hill on behalf of the Gay, Lesbian & Straight Education Network, or GLSEN, to urge passage of anti-bullying legislation with LGBT protections known as the Student Non-Discrimination Act and the Safe Schools Improvement Act.
Daryl Presgraves, a GLSEN spokesperson, said GLSEN started working with Aiken four years ago, and in addition to wanting to use his platform to protect LGBT youth, he showed a specific interest in policy.
“After he gave a powerful and moving speech at a congressional briefing we held in 2010 in support of the Safe Schools Improvement Act and Student Non-Discrimination Act, it wouldn’t have surprised any of us at GLSEN if you told us that he would consider running for office one day,” Presgraves said. “He has a clear passion for helping others and recognizes the power to do so through policy.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Rehoboth Beach
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
$4.5 million listing includes real estate; business sold separately
Gay gasps could be heard around the DMV earlier this week when a real estate listing for Rehoboth Beach’s iconic Blue Moon bar and restaurant hit social media.
Take a breath. The Moon is for sale but the longtime owners are not in a hurry and are committed to preserving its legacy as a gay-friendly space.
“We had no idea the interest this would create,” Tim Ragan, one of the owners, told the Blade this week. “I guess I was a little naive about that.”
Ragan explained that he and longtime partner Randy Haney are separating the real estate from the business. The two buildings associated with the sale are listed by Carrie Lingo at 35 Baltimore Ave., and include an apartment, the front restaurant (6,600 square feet with three floors and a basement), and a secondary building (roughly 1,800 square feet on two floors). They are listed for $4.5 million.
The bar and restaurant business is being sold separately; the price has not been publicly disclosed.
But Ragan, who has owned the Moon for 20 years, told the Blade nothing is imminent and that the Moon remains open through the holidays and is scheduled to reopen for the 2026 season on Feb. 10. He has already scheduled some 2026 entertainment.
“It’s time to look for the next people who can continue the history of the Moon and cultivate the next chapter,” Ragan said, noting that he turns 70 next year. “We’re not panicked; we separated the building from the business. Some buyers can’t afford both.”
He said there have been many inquiries and they’ve considered some offers but nothing is firm yet.
Given the Moon’s pioneering role in queering Rehoboth Beach since its debut 44 years ago in 1981, many LGBTQ visitors and residents are concerned about losing such an iconic queer space to redevelopment or chain ownership.
“That’s the No. 1 consideration,” Ragan said, “preserving a commitment to the gay community and honoring its history. The legacy needs to continue.” He added that they are not inclined to sell to one of the local restaurant chains.
You can view the real estate listing here.
‘Dogs of Venice’ looks at love lost and rediscovered
A Wider Bridge to close
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Lighting candles in a time of exhaustion
Why queer spaces often fail South Asian women
